T14	total-participants 1204 1213	Sixty-two
T15	total-participants 1244 1246	50
T16	intervention-participants 1264 1266	27
T17	control-participants 1287 1289	23
T18	age 1322 1338	48 (range 31-75)
T21	iv-bin-percent 1446 1451	29.6%
T22	cv-bin-percent 1459 1464	47.8%
T23	outcome 1483 1486	pCR
T24	iv-bin-percent 1492 1497	25.9%
T25	cv-bin-percent 1505 1510	30.4%
T26	outcome 1691 1697	anemia
T27	outcome 1699 1710	neutropenia
T28	outcome 1712 1729	rash/desquamation
T29	outcome 1735 1743	vomiting
T30	cv-bin-abs 1768 1771	one
T31	outcome 1780 1799	grade 3 pneumonitis
T32	outcome 1819 1842	No grade 3/4 stomatitis
T1	intervention 49 105	neoadjuvant chemotherapy with paclitaxel followed by FEC
T2	control 117 173	combination of paclitaxel and everolimus followed by FEC
T3	eligibility 578 604	patients with primary TNBC
T8	outcome 1609 1619	12-week RR
T4	control 1299 1305	TR-FEC
T6	outcome 1898 1912	well tolerated
T5	outcome-Measure 1107 1150	12-week clinical response rate (12-week RR)
T7	outcome-Measure 1152 1188	pathological complete response (pCR)
T9	outcome-Measure 1194 1202	toxicity
T10	outcome 1412 1426	Twelve-week RR
